journal article·2022

Clinical big-data-based design of GLUT2-targeted carbon nanodots for accurate diagnosis of hepatocellular carcinoma

Hye Jin Heo, Yoonsang Park, Jung Hee Lee, Yujin Kim, Eun Kyoung Kim, Ga Hyun Kim, Yeuni Yu, So Youn Park, Hie Bum Seo, Kyoungjune Pak, Tae Sik Goh, Sehyeon Park, Sae-Ock Oh, Woosung Kwon, Yun Hak Kim

Nanoscale· Volume 14· Issue 45
Publisher page

Abstract

Despite advances in diagnostic and therapeutic methods, the prognosis of patients with hepatocellular carcinoma (HCC) remains poor due to the delay in diagnosis. Herein, we aimed to discover a highly sensitive and specific biomarker for HCC based on genomic big data analysis and create an HCC-targeted imaging probe using carbon nanodots (CNDs) as contrast agents. In genomic analysis, we selected glucose transporter 2 (GLUT2) as a potential imaging target for HCC. We confirmed the target suitability by immunohisto-chemistry tests of 339 patient samples, where 81.1% of the patients exhibited underexpression of GLUT2, i.e., higher GLUT2 intensity in non-tumor tissues than in tumor tissues. To visualize GLUT2, we conjugated CNDs with glucosamine (GLN) as a targeting ligand to yield glucosamine-labeled CNDs (GLN-CNDs). A series of in vitro and in vivo experiments were conducted on GLUT2-modified HepG2 cells to confirm the specificity of the GLN-CNDs. Since the GLUT2 expression is higher in hepatocytes than in HCC cells, the GLUT2-targeted contrast agent is highly attached to normal cells. However, it is possible to produce images in the same form as the images obtained with a cancer cell-targeted contrast agent by inverting color scaling. Our results indicate that GLUT2 is a promising target for HCC and that GLN-CNDs may potentially be used as targeted imaging probes for diagnosing HCC.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Carbon and Quantum Dots Applications · Nanocluster Synthesis and Applications · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Anatomy, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea

Institute of Advanced Materials and Systems, Sookmyung Women's University, Seoul 04310, Republic of Korea

Nano Convergence Technology Research Center, Korea Electronics Technology Institute (KETI), Seongnam 13509, Republic of Korea

Department of Pathology, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea

Department of Chemical and Biological Engineering, Sookmyung Women's University, Seoul 04310, Republic of Korea

Interdisciplinary Program of Genomic Data Science, Pusan National University, Yangsan 50612, Republic of Korea

Biomedical Research Institute, Pusan National University Hospital, Yangsan 50612, Republic of Korea

Gene & Cell Therapy Research Center for Vessel-associated Diseases, Pusan National University, Yangsan 50612, Republic of Korea

Department of Radiology, School of Medicine, Pusan National University, Pusan National University Hospital, Yangsan 50612, Republic of Korea

Department of Nuclear Medicine, Pusan National University Hospital, Yangsan 50612, Republic of Korea

Department of Orthopaedic Surgery, Pusan National University Hospital, Yangsan 50612, Republic of Korea

Department of Biomedical Informatics, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea

Funding

Ministry of Health and Welfare · National Research Foundation of Korea · Korea Health Industry Development Institute

References (46)

Show source-provided references
1. El-Serag · N. Engl. J. Med. · 2011 · 365 · 111810.1056/NEJMra1001683 ↗
2. Khalaf · Clin. Gastroenterol. Hepatol. · 2017 · 15 · 27310.1016/j.cgh.2016.07.033 ↗
3. Ayoub · Ther. Adv. Med. Oncol. · 2019 · 11 · 175883591986912010.1177/1758835919869120 ↗
4. Heimbach · Hepatology · 2018 · 67 · 35810.1002/hep.29086 ↗
5. Berardi · J. Hepatol. · 2020 · 72 · 7510.1016/j.jhep.2019.08.032 ↗
6. Toh · J. Hepatol. · 2020 · 72 · 10410.1016/j.jhep.2019.08.035 ↗
7. Bruix · Hepatology · 2011 · 53 · 102010.1002/hep.24199 ↗
8. Kim · Oncotarget · 2017 · 8 · 6838110.18632/oncotarget.20266 ↗
9. Qin · World J. Gastroenterol. · 2002 · 8 · 19310.3748/wjg.v8.i2.193 ↗
10. Altekruse · J. Clin. Oncol. · 2009 · 27 · 148510.1200/JCO.2008.20.7753 ↗
11. European Association for the Study of the Liver · J. Hepatol. · 2018 · 69 · 18210.1016/j.jhep.2018.03.019 ↗
12. Singal · Aliment. Pharmacol. Ther. · 2009 · 30 · 3710.1111/j.1365-2036.2009.04014.x ↗
13. Di Bisceglie · J. Hepatol. · 2005 · 43 · 43410.1016/j.jhep.2005.03.019 ↗
14. Hoshida · Cancer Res. · 2009 · 69 · 738510.1158/0008-5472.CAN-09-1089 ↗
15. Villanueva · Annu. Rev. Med. · 2010 · 61 · 31710.1146/annurev.med.080608.100623 ↗
16. Yamashita · Cancer Res. · 2008 · 68 · 145110.1158/0008-5472.CAN-07-6013 ↗
17. Chou · Ann. Intern. Med. · 2015 · 162 · 69710.7326/M14-2509 ↗
18. Hanna · Abdom. Radiol. · 2016 · 41 · 7110.1007/s00261-015-0592-8 ↗
19. Lee · Radiology · 2015 · 275 · 9710.1148/radiol.14140690 ↗
20. Avril · J. Nucl. Med. · 2004 · 45 · 930
21. Li · Eur. J. Nucl. Med. Mol. Imaging · 2017 · 44 · 173210.1007/s00259-017-3724-2 ↗
22. Adekola · Curr. Opin. Oncol. · 2012 · 24 · 65010.1097/CCO.0b013e328356da72 ↗
23. Joost · Mol. Membr. Biol. · 2001 · 18 · 24710.1080/09687680110090456 ↗
24. Navale · Biophys. Rev. · 2016 · 8 · 510.1007/s12551-015-0186-2 ↗
25. Cheng · Angew. Chem., Int. Ed. · 2019 · 58 · 1339410.1002/anie.201907754 ↗
26. Saito · Cancer Res. · 2004 · 64 · 257210.1158/0008-5472.CAN-03-3631 ↗
27. Cheng · Nat. Rev. Drug Discovery · 2015 · 14 · 23910.1038/nrd4503 ↗
28. Du · Nano Lett. · 2019 · 19 · 361810.1021/acs.nanolett.9b00630 ↗
29. Medintz · Nat. Mater. · 2005 · 4 · 43510.1038/nmat1390 ↗
30. Croissant · Nat. Rev. Mater. · 2020 · 5 · 88610.1038/s41578-020-0230-0 ↗
31. Fabbro · Chem. Commun. · 2012 · 48 · 391110.1039/c2cc17995d ↗
32. Martín · Adv. Funct. Mater. · 2019 · 29 · 190176110.1002/adfm.201901761 ↗
33. Bobo · Pharm. Res. · 2016 · 33 · 237310.1007/s11095-016-1958-5 ↗
34. Brannon-Peppas · Adv. Drug Delivery Rev. · 2004 · 56 · 164910.1016/j.addr.2004.02.014 ↗
35. Kim · Adv. Mater. · 2018 · 30 · 170146010.1002/adma.201701460 ↗
36. Li · J. Nanomater. · 2012 · 2012 · 54838910.1155/2012/548389 ↗
37. Baker · Angew. Chem., Int. Ed. · 2010 · 49 · 672610.1002/anie.200906623 ↗
38. Hola · Nano Today · 2014 · 9 · 59010.1016/j.nantod.2014.09.004 ↗
39. Zheng · Small · 2015 · 11 · 162010.1002/smll.201402648 ↗
40. Sun · J. Am. Chem. Soc. · 2006 · 128 · 775610.1021/ja062677d ↗
41. Du · Small · 2019 · 15 · e180508710.1002/smll.201805087 ↗
42. Park · J. Mater. Chem. B · 2020 · 8 · 893510.1039/D0TB01334J ↗
43. Zhao · Carbon · 2015 · 85 · 30910.1016/j.carbon.2014.12.045 ↗
44. Li · ACS Omega · 2020 · 5 · 1591110.1021/acsomega.0c01054 ↗
45. Thorens · Diabetologia · 2015 · 58 · 22110.1007/s00125-014-3451-1 ↗
46. Kim · Oncogene · 2011 · 30 · 295410.1038/onc.2011.22 ↗